Kausikh Therapeutics Private Limited - Due diligence report

A 360° intelligence report on Kausikh Therapeutics: trust score, financial health, credit view, compliance, directors, growth and distress s…

2000-04-19 Gerugambakkam, Tamil Nadu Active Unlisted Active Compliant
Share
KT Kausikh Therapeutics Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Kausikh Therapeutics — 360° Intelligence Report

Generated from MCA filings & public records
84/100
Trust Score
Low Risk

Kausikh Therapeutics is assessed as Low Risk with a Trust Score of 84/100. Kausikh Therapeutics is an active private limited indian non-government company incorporated in 2000, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. Kausikh Therapeutics Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
84/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
74/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
75/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
85/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Profitable - internal accruals available.
  • Externally credit-rated (B+).

Charges position: 4 open (56.48 cr) · 4 satisfied (7.83 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others4 48.0 cr
Indian Bank2 48.0 cr
Indian Overseas Bank1 48.0 cr
Hdfc Bank Limited1 48.0 cr
Compliance Score: 74/100 Moderate
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • Litigation present in 2 court forum(s).
  • 1 active GST registration(s).
Legal cases on record (2)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
VAIDHYANATHEN NEELAKANTAN 01234567 Director 01/04/2018 6 yrs Approved
VAIDHYANATHAN RAMASUBRAHMANIAN 01234567 Director 01/04/2018 6 yrs Approved
ANANTHARAMKRISHNAN VAIDHYANATHEN 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2024 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
2 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Key managerial personnel: VAIDHYANATHEN NEELAKANTAN (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 85 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Profit expanded 2.1x year-on-year.
Net margin improved to 24%.
Operating for 26+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
4 open charge(s) registered - assets are encumbered.
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence82/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment61/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 4 open charge(s) of 56.48 cr already registered.
  • Compliance record supports lending.
Investor view81/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
16 Sep 2025
Charge created
Others - 2.00 cr
25 Jul 2025
Charge created
Others - 28.46 Lakh
31 Mar 2024
Latest balance sheet
Filed with ROC
15 Oct 2020
Charge satisfied
Indian Bank
29 Feb 2020
Charge created
Others - 38.19 cr
26 Apr 2019
Charge created
Others - 16.00 cr
25 Mar 2014
Securities allotted
395200.00 Equity Shares - 39.52 Lakh raised
24 Mar 2014
Securities allotted
440000.00 Equity Shares - 44.00 Lakh raised
10 Feb 2014
Director ceased
LALITHA MAHADEVAN
03 Feb 2014
Charge created
Indian Bank - 90.00 Lakh
26 Jan 2014
Charge satisfied
Indian Bank
04 Oct 2011
Charge satisfied
Hdfc Bank Limited
12 Apr 2010
Charge satisfied
Indian Overseas Bank
25 Mar 2010
Charge created
Indian Bank - 3.93 cr
10

Key Observations

Auto-generated from the data above
Revenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - leverage worth monitoring.
Net worth is positive.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of B+ from Crisil.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Cu-V-Kar Genetic Medicine Private Limited U02423TN2007PTC061947 Chennai, Tamil Nadu, India
Auro Laboratories L33125MH1989PLC051910 Thane, Maharashtra, India
Rv Lifesciences Limited U24230MH1991PLC063442 Aurangabad, Maharashtra, India
Pharmanza (India) U24230GJ2009PTC055895 Khambhat, Gujarat, India
Asoj Soft Caps U24110MH1981PTC024872 Mumbai, Maharashtra, India
Nikvin Healthcare (India) Private Limited U24231DL2005PTC136780 New Delhi, Delhi, India
Anugrah U24117GJ2001PTC040257 Vadodara, Gujarat, India
Simpexpharma U33112DL1997PTC085657 New Delhi, Delhi, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Kausikh Therapeutics before audits and certifications: compliance score 74/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Kausikh Therapeutics: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 85/100, margin trends, ownership structure and peer set for Kausikh Therapeutics - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 84/100, distress signals and MSME payment-delay disclosures - know whether Kausikh Therapeutics pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Kausikh Therapeutics - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Kausikh Therapeutics an active company?

Kausikh Therapeutics has MCA status “Active” with a compliance score of 74/100 (Moderate).

Is Kausikh Therapeutics financially healthy?

Kausikh Therapeutics has a Financial Health Score of 75/100 (Low Risk) based on its filed financial statements.

Should I do business with Kausikh Therapeutics?

Its overall Trust Score is 84/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Kausikh Therapeutics?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.

Does Kausikh Therapeutics have loans or charges against its assets?

4 open charge(s) are registered against its assets, and 4 earlier charge(s) stand satisfied.

Is Kausikh Therapeutics up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 74/100 (Moderate).

Is it risky to lend to Kausikh Therapeutics?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.